Eli Lilly Says New Data Can Potentially Provide Path To Improved Donanemab Profile By Lower Risk Of Imaging Abnormalities In Patients With Early Alzheimer's

On Tuesday, Eli Lilly And Co (NYSE:LLY) released results from the TRAILBLAZER-ALZ 6 Phase 3b study to investigate different dosing regimens of donanemab and their effect on amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in adults with early symptomatic Alzheimer’s disease.

ARIA-E is a type of MRI finding that can occur in patients with Alzheimer’s disease who are taking anti-amyloid beta (Aβ) immunotherapies.

Also Read: Eli Lilly Alzheimer’s Drug Faces Tough Road In UK, Price Watchdog NICE Says Donanemab Is Not Cost-Effective

The data showed a reduction in amyloid-related imaging abnormalities with edema/effusion (ARIA-E) at the 24-week primary endpoint for ...